2021

San Mateo, California, November 12, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will give an oral presentation on consolidated results from the Phase 2 FASCINATE-1 trial of Sagimet’s lead clinical candidate TVB-2640 in patients in the U.S. and China with nonalcoholic steatohepatitis (NASH) on November 14 at The Liver Meeting 2021. The presentation is entitled “Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China.”

FOR IMMEDIATE RELEASE San Mateo, California, October 4, 2021– Sagimet Biosciences, a clinical-stage biotechnology company, announced today that consolidated results

FOR IMMEDIATE RELEASE San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio

San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology – the official journal of the American Gastroenterological Association – published results from the company’s FASCINATE-1 Phase 2a clinical trial evaluating TVB-2640 in patients with non-alcoholic steatohepatitis (NASH).

San Mateo, California, May 3, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective

San Mateo, California, April 23, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective

In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic steatohepatitis (NASH)  San

Dr. Martins Joins the Company to Help Advance Sagimet’s Pipeline of FASN Inhibitors  San Mateo, California, March 11, 2021 –

[vc_row type=”in_container” full_screen_row_position=”middle” scene_position=”center” text_color=”dark” text_align=”left” overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default”

[vc_row type=”in_container” full_screen_row_position=”middle” scene_position=”center” text_color=”dark” text_align=”left” overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default”